Study: Anti-NGF drug could be effective treatment for OA patients

04/16/2013 | InternalMedicineNews.com (free registration)

Treatment of osteoarthritis of the hip with tanezumab, an anti-nerve growth factor, was found to significantly improve pain and physical function after 16 weeks, according to results from a Phase III study of 621 patients with painful hip OA. According to the study, tanezumab could be useful in treating OA patients who can't tolerate or don't respond to nonopioid treatments.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA